


I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EV 438997269 US, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: 11/2/04

Signature:

Victoria Parker
(Victoria Parker)

Docket No.: 62075CIP(51590)
(PATENT)



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Gavril W. Pasternak et al.

Application No.: 10/827,063

Confirmation No.: 2362

Filed: April 19, 2004

Art Unit: 1614

For: COMPOSITIONS AND METHODS FOR
REVERSAL OF DRUG RESISTANCE

Examiner: Not Yet Assigned

INFORMATION DISCLOSURE STATEMENT (IDS)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed before the mailing date of a first Office Action on the merits as far as is known to the undersigned (37 CFR 1.97(b)(3)).

A copy of each reference on the PTO/SB/08 is attached.

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 04-1105, under Order No. 62075CIP(51590). A duplicate copy of this paper is enclosed.

Dated:

Respectfully submitted,

By Amy Leahy
Amy M. Leahy
Registration No.: 47,739
EDWARDS & ANGELL, LLP
P.O. Box 55874
Boston, Massachusetts 02205
(203) 975-7505
Attorney for Applicant



PTO/SB/08a/b (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				Complete if Known	
				Application Number	10/827,063-Conf. #2362
				Filing Date	April 19, 2004
				First Named Inventor	Gavril W. Pasternak
				Art Unit	1614
				Examiner Name	Not Yet Assigned
Sheet	1	of	2	Attorney Docket Number	62075CIP(51590)

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)	MM-DD-YYYY		
AA	US-6,306,876-B1	10-23-2001	Carson et al.		
AB	US-6,057,371	05-02-2000	Glennon		
AC	US-5,993,777	11-30-1999	John et al.		
AD	US-5,767,125	06-16-1998	Crain et al.		
AE	US-5,580,750	12-03-1996	Doglia et al.		
AF	US-5,403,574	04-04-1995	Piwnica-Worms		
AG	US-5,236,714	08-17-1993	Lee et al.		
AH	US-Re. 36,547	02-01-2000	Crain et al.		

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	MM-DD-YYYY		T ⁶

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
CA	Bowen WD, et al (1997) Proceedings of the Eighty-Eighth Annual Meeting of the American Association for Cancer Research, Vol. 38.				T ²
CB	Bowen WD, Sigma receptors: recent advances and new clinical potentials, <i>Pharmaceutica Acta Helveticae</i> 74(2-3) (2000) 211-218.				
CC	Brent PJ, et al (1995) <i>Eur. J. Pharmacol.</i> 278(2): 151-60				
CD	Callaghan R, et al (1993) <i>J. Biol. Chem.</i> 268(21): 16059-64				
CE	Callaghan R, et al (1995) <i>Biochim. Biophys. Acta</i> 1236(1): 155-62				
CF	Conseil et al, (2001) <i>Biochemistry</i> 40(8): 2564-71				
CG	Fine et al, (1996) <i>Oncologist</i> 1(4): 261-268				
CH	Garrigues et al, (2002) <i>Proc. Natl. Acad. Sci. USA</i> 99(16): 10347-52				
CI	Georg A, et al (1991) <i>J. Pharmacol. Exp. Ther.</i> 259: 479-83				
CJ	Hellewell SB, et al (1990) <i>Brain Res.</i> 527: 224-253				
CK	Kramer et al, (1995) <i>Br. J. Cancer</i> 71(4): 670-5.				
CL	Krishan et al., Synergistic effect of prochlorperazine and dipyridamole on the cellular retention and cytotoxicity of doxorubicin, <i>Clinical Cancer Research</i> Vol. 6, 1508-1517, April 2000.				
CM	Laredo et al, (1994) <i>Blood</i> 84(1): 229-37				
CN	Largent BL, et al (1987) <i>Mol. Pharmacol.</i> 32(6): 772-84.				
CO	Litman et al, (1997) <i>Biochim. Biophys. Acta</i> 136(2): 169-76				
CP	Loo et al., The human multidrug resistance P-glycoprotein is inactive when its maturation is inhibited: potential for a role in cancer chemotherapy, <i>The FASEB Journal</i> Vol 13, 1724-1732, October 1999.				

Examiner Signature	Date Considered
--------------------	-----------------

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				Complete if Known	
				Application Number	10/827,063-Conf. #2362
				Filing Date	April 19, 2004
				First Named Inventor	Gavril W. Pasternak
				Art Unit	1614
				Examiner Name	Not Yet Assigned
Sheet	2	of	2	Attorney Docket Number	62075CIP(51590)

CQ	Matsuo et al, (2001) J. Control Release 77(1-2):77-86
CR	Pan et al, (2001) Chin. Med. J. 114(9): 929-32
CS	Pearce et al. (1989) Proc. Natl. Acad. Sci. USA 86: 5128-32
CT	Romsicki et al, (2001) Biochemistry 40(23): 6937-47
CU	Ross, D.D. (2000) Leukemia 14: 467-473
CV	Scotto et al. (1986) Science 232(4751): 751-5
CW	Schinkel et al, (1991) Cancer Res. 51(10): 2628-35
CX	Shtil, A.A. (2001) Curr. Drug Targets 2(1): 57-77
CY	Sikic et al, (1997) Cancer Chemother. Pharmacol. 40 (Suppl.): S13-S19
CZ	Tan, et al. (2000) Curr. Opin. Oncol. 12(5): 450-8
CA1	Thiebaut F, et al J. Histochem. Cytochem. 37(2): 159-64
CB1	van Den Elsen et al, (1999) Proc. Natl. Acad. Sci. 96(24): 13679-84
CC1	Vilner BJ, et al (1995) Cancer Res. 55(2): 408-13

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

184183